Skip to main content
Clinical Trials/CTRI/2022/05/042657
CTRI/2022/05/042657
Recruiting
未知

The Descriptive Study on Assessment of the effects of combination of SGLT 2 Inhibitors (SGLT2-I) and Renin Angiotensin Aldosterone System (RAAS) Blockers (RAAS-I) on the renal functions of patients of diabetic kidney disease (DKD) on the population of patients from the Southern part of West Bengal (SGRAAS-DKD) - SGRAAS-DKD

Thakurpukur Medical Society0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: E112- Type 2 diabetes mellitus with kidney complications
Sponsor
Thakurpukur Medical Society
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Observational

Investigators

Sponsor
Thakurpukur Medical Society

Eligibility Criteria

Inclusion Criteria

  • Diagnosed case of Diabetic Kidney Disease
  • Type 2 Diabetes Mellitus with
  • a. Urinary Spot ACR \> 30 mg/g
  • b. eGFR, calculated by CKD\-EPI \< 90 mL/min/1\.73 M2
  • c. Receiving RAAS\-I for at least 4 weeks
  • d. Recently initiated on SGLT2\-I

Exclusion Criteria

  • 1\.eGFR, calculated by CKD\-EPI \<30 mL/min/1\.73 M2
  • 2\.Non\-consenting patients
  • 3\.Doubt about the nature of kidney disease. Suspicion of nondiabetic renal disease such as renal artery stenosis, glomerular disease or other systemic disorders with renal involvement
  • 4\.Ongoing active infection, sepsis or symptomatic UTI, active malignancy
  • 5\.History of symptomatic UTI in the past 6 months

Outcomes

Primary Outcomes

Not specified

Similar Trials